Trial Profile
Multicenter, Open-Label, Single-Arm Study to Evaluate Long-Term Safety, Tolerability, and Effectiveness of 10 mg/kg BID Olesoxime in Patients With Spinal Muscular Atrophy
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 22 Dec 2021
Price :
$35
*
At a glance
- Drugs Olesoxime (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions
- Acronyms OLEOS
- Sponsors Roche
- 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database.
- 16 Dec 2021 This trial has been completed in France, according to European Clinical Trials Database.
- 18 Apr 2019 This trial has been completed in Poland, according to European Clinical Trials Database.